MUC-1 recombinant adenoviral vector vaccine (Sidney Kimmel Cancer Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMUC-1 recombinant adenoviral vector vaccine (Sidney Kimmel Cancer Center)
Drug Alias Namedual CD40 costimulator/MUC-1 antigen (adenoviral vector vaccine) (Sidney Kimmel Cancer Center)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonistsMucin-1 modulators
TargetsMucin-1Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsColonic NeoplasmsBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSidney Kimmel Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSidney Kimmel Cancer Center
Active IndicationsN/A
Inactive IndicationsColonic NeoplasmsBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A